Amino‑Alcohol Ionizable Lipids for Next‑Generation Nucleic Acid Delivery (Amino Alcohol Ionizable Lipids, Tech ID: 22‑017)
Technology Overview: This technology introduces a novel class of amino‑alcohol‑based ionizable lipids designed to improve the delivery of nucleic acids, including mRNA and siRNA. The lipids exhibit pH‑responsive ionization, enabling efficient endosomal escape while maintaining low toxicity under physiological conditions. Their chemical tunability allows optimization for encapsulation efficiency, stability, and in‑vivo performance, making them well suited for lipid nanoparticle (LNP) formulations.
Industry Pain Point: Current ionizable lipids used in LNPs face trade‑offs between delivery efficiency, toxicity, and manufacturability.
NJIT Solution: These lipids provide enhanced delivery efficiency with improved safety profiles, supporting next‑generation RNA therapeutics.
Key Features & Advantages
- pH‑responsive ionization for efficient endosomal escape
- Tunable chemistry for optimized delivery
- Improved safety profile
- Compatible with established LNP manufacturing
Development Stage: TRL 3–4 – Early‑stage formulation and in‑vitro validation.
Target Markets
- mRNA therapeutics
- Gene therapy platforms
- Vaccine delivery systems
Market Opportunity
- Global lipid nanoparticle market (2026): ~$6B
- CAGR: ~13–15%
- Projected market size (2035): ~$20–22B
Commercial & IP Details
Inventors: Zhongyu Li, Xiaoyang Xu